Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Experts Warn Of Dangers In Australia's Mass H1N1 Flu Vaccination Plan

This article was originally published in PharmAsia News

Executive Summary

Some Australian infectious-disease experts urged the government to cancel a plan to vaccinate as many people as possible against the H1N1 flu. They warned of a contamination risk that could spread blood-borne diseases. The Australasian Society for Infectious Disease sent a letter to the Health Ministry saying the risk lies in multi-dose vials for the vaccine supplied by CSL. The organization urged a delay in the mass-vaccination plan until the vaccine can be issued with single-dose vials. The letter said the medical community already knows multi-dose vials often transmit infectious diseases, some resulting in death. (Click here for more

You may also be interested in...



Coronavirus Update: Can IL-6 Drugs Cut Deaths? Kevzara Trials Starts In Worst Hit Countries

A round up of news from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.

QUOTED. 31 March 2020. US FDA.

The US FDA published on 29 March an emergency temporary guidance that relaxes oversight of certain sterilizers, disinfectant devices and air purifiers intended to kill the SARS-CoV-2 virus. See what the agency said about it here.

Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies

Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.

UsernamePublicRestriction

Register

SC072540

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel